Features

High-potency manufacturing, for both active pharmaceutical ingredients and drug products, continues to be an active area of investment by CDMOs/CMOs. What are some key moves, both recent and announced expansions by CDMOs/CMOs?

The International Monetary Fund has downgraded its outlook for the global economy next year based on the effects of the war in Ukraine, global inflation that requires interest rate hikes, and a slowdown in China.

Which late-stage drug candidates or recently approved drugs of the large bio/pharmaceutical companies are poised for high peak-sales potential or potentially blockbuster status? DCAT Value Chain Insights takes an inside look of the key pipeline contenders.

The European Commission has approved $131 million to BASF to support its production of renewable hydrogen, with the aims of decarbonizing its chemical production processes. Is hydrogen power a solution to the EU’s energy crisis?

A slate of blockbuster drugs is scheduled to come off patent in the near term. Which products and companies face generic-drug incursion? Plus the latest numbers and trends in US generic drug approvals.

Novartis CEO Vas Narasimhais outlined the company’s strategy of being a “pure-play” innovator drug company focused on five core therapeutic areas with eight potential multi-billion drugs in play.  

As we near the fourth quarter of 2022, what have been the key mergers and acquisitions thus far in the CDMO/CMO sector and what new CDMOs/CMOs have entered the market? DCAT Value Chain Insights takes a look.

How is current market volatility, led by inflationary pressures, supply-chain disruptions, and geopolitical uncertainty, impacting sourcing and supply decisions? A look at what is on the industry’s radar.

The European Commission proposed this week an emergency intervention in Europe’s energy markets to address recent dramatic price rises as the EU faces the effects of a severe mismatch between energy demand and supply. What is in the proposal?

What are the key issues and trends in play for the rest of 2022? From energy supply to inflationary pressures to new bio/pharmaceutical products launches, DCAT Value Chain Insights takes an inside look of what may be next.